Swiss National Bank Boosts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Swiss National Bank boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 210,100 shares of the biopharmaceutical company’s stock after acquiring an additional 2,500 shares during the quarter. Swiss National Bank owned about 0.18% of Catalyst Pharmaceuticals worth $4,385,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Rhumbline Advisers increased its holdings in Catalyst Pharmaceuticals by 0.3% in the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock valued at $6,518,000 after buying an additional 952 shares in the last quarter. Handelsbanken Fonder AB increased its stake in Catalyst Pharmaceuticals by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock valued at $740,000 after purchasing an additional 1,000 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Catalyst Pharmaceuticals in the 4th quarter valued at approximately $27,000. Farther Finance Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after purchasing an additional 1,495 shares during the last quarter. Finally, KBC Group NV boosted its position in Catalyst Pharmaceuticals by 48.8% during the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,542 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Buying and Selling

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 0.1 %

NASDAQ:CPRX opened at $25.72 on Wednesday. The company has a market cap of $3.12 billion, a P/E ratio of 21.80, a P/E/G ratio of 3.31 and a beta of 0.84. The firm’s 50 day moving average is $22.53 and its two-hundred day moving average is $21.72. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $26.16.

Analysts Set New Price Targets

Several research firms have recently issued reports on CPRX. Stephens reaffirmed an “overweight” rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Robert W. Baird lifted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, March 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.